BioWorld

Oct. 14, 2004

View Archived Issues

AtheroGenics Drops AGIX-4207 After Phase II Miss In Arthritis

AtheroGenics Inc. is discontinuing the development of one of its investigational drugs following a Phase II failure. (BioWorld Today) Read More

Panel: Novelty, Strong Science Keys To Snagging VC Funding

Read More

VistaGen, Sanwa Studying ESCs For Use In Diabetes

Read More

Halozyme Privately Brings In $14M For Hyaluronidase

Read More

Other News To Note

Read More